NCCS and Colleagues Comment on FDA Strategies Regarding Drug Shortages
NCCS joined colleagues in the cancer patient and provider community in providing advice to the Food and Drug Administration (FDA) regarding strategies to anticipate, mitigate, and report shortages of drugs and biologicals. In the last several years, cancer patients and many others with serious and life-threatening illnesses have experienced disruptions in supply for a number of drugs that provide important, and sometimes life-saving, treatment. The Food and Drug Administration Improvement and Safety Act of 2012 requires FDA to prepare a strategic plan for addressing drug shortages.
NCCS and its colleagues supplied advice as part of a formal comment period through which FDA sought public input regarding approaches to address drug shortages.
